"The Center for Retina & Macular Disease has been serving Central Florida since 1991, providing expert, compassionate treatment for disorders and diseases of the retina. Our six highly skilled physicians are dedicated to the highest standard of care and have been nationally recognized for patient care, education and research."

During the past decade, Center for Retina and Macular Disease conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 13 clinical trials were completed, i.e. on average, 39.4% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 7 clinical trials were completed. i.e. 53.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Retina and Macular Disease" #1 sponsor was "Clearside Biomedical, Inc." with 5 trials, followed by "ThromboGenics" with 5 trials sponsored, "Allergan" with 4 trials sponsored, "Kodiak Sciences Inc" with 3 trials sponsored and "Lpath, Inc." with 3 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Retina and Macular Disease" #1 collaborator was "Duke University" with 2 trials as a collaborator, "National Eye Institute (NEI)" with 2 trials as a collaborator, "Trial Runners, LLC" with 2 trials as a collaborator, "Clinical Trials Resource Group, LLC" with 1 trials as a collaborator and "Milton S. Hershey Medical Center" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Center for Retina and Macular Disease" are "Diabetic Macular Edema" (9 trials), "Macular Degeneration" (9 trials), "Diabetic Retinopathy" (5 trials), "Macular Edema" (4 trials) and "Choroidal Neovascularization" (3 trials). Many other conditions were trialed in "Center for Retina and Macular Disease" in a lesser frequency.

Most popular intervention types in "Center for Retina and Macular Disease" are "Drug" (40 trials), "Other" (8 trials), "Biological" (4 trials), "Combination Product" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Sham Procedure" (5 trials), "Ranibizumab" (4 trials), "Aflibercept" (3 trials) and "KSI-301" (3 trials). Other intervention names were less common.

The vast majority of trials in "Center for Retina and Macular Disease" are 50 trials for "All" genders.

Currently, there are NaN active trials in "Center for Retina and Macular Disease". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Center for Retina and Macular Disease, 1 suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Retina and Macular Disease, 11 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".